The concept of bio-corona in modulating the toxicity of engineered nanomaterials (ENM)

Toxicology and Applied Pharmacology

Volumn 299, Issue , 2016, Pages 53-57

  Westmeier, Dana ^a   Stauber, Roland H ^a   Docter, Dominic ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Corona; Nanomedicine; Nanotoxicology

Indexed keywords

NANOCARRIER; NANOMATERIAL; NANOPARTICLE; PROTEIN CORONA; BIOMATERIAL;

ARTICLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; NANOENGINEERING; NANOTOXICOLOGY; PROTEIN INTERACTION; ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; NANOTECHNOLOGY; PHYSIOLOGY; PROCEDURES; TISSUE DISTRIBUTION; TRENDS;

ANIMALS; BIOCOMPATIBLE MATERIALS; HUMANS; NANOSTRUCTURES; NANOTECHNOLOGY; TISSUE DISTRIBUTION;

EID: 84961615814     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.11.008     Document Type: Article

References (59)

1. Bertrand N., et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014, 66:2-25.
2. Cedervall T., et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(7):2050-2055.
3. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148(2):135-146.
4. Dobrovolskaia M.A., McNeil S.E. Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin. Drug Deliv. 2015, 12(7):1163-1175.
5. Docter D., et al. The nanoparticle biomolecule corona: lessons learned - challenge accepted?. Chem. Soc. Rev. 2015, 44(17):6094-6121.
6. Docter D., et al. No king without a crown - impact of the nanomaterial-protein corona on nanobiomedicine. Nanomedicine (Lond) 2015, 10(3):503-519.
7. Fabian E., et al. Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Arch. Toxicol. 2008, 82(3):151-157.
8. Farrera C., Fadeel B. It takes two to tango: understanding the interactions between engineered nanomaterials and the immune system. Eur. J. Pharm. Biopharm. 2015.
9. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5(3):161-171.
10. Helou M., et al. Time-of-flight magnetic flow cytometry in whole blood with integrated sample preparation. Lab Chip 2013, 13(6):1035-1038.
11. Hillaireu H., Couvreur P. Nanocarriers[U+FF92] entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 2009, 66:2873-2896.
12. Huang H., et al. Learning from biology: synthetic lipoproteins for drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2015, 7(3):298-314.
13. Kim H.R., et al. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol. Pharm. 2008, 5(4):622-631.
14. Kirchner C., et al. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Lett. 2005, 5(2):331-338.
15. Lademann O., et al. Stimulation of the penetration of particles into the skin by plasma tissue interaction. Laser Phys. Lett. 2011, 8(10):758-764.
16. Lee Y.K., et al. Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity. Int. J. Nanomedicine 2015, 10:97-113.
17. Lehmann A.D., et al. Fluorescent-magnetic hybrid nanoparticles induce a dose-dependent increase in proinflammatory response in lung cells in vitro correlated with intracellular localization. Small 2010, 6(6):753-762.
18. Li M., et al. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano 2010, 4(11):6303-6317.
19. Lipka M., et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 2010, 31(25):6574-6581.
20. Martel J., et al. Comprehensive proteomic analysis of mineral nanoparticles derived from human body fluids and analyzed by liquid chromatography-tandem mass spectrometry. Anal. Biochem. 2011, 418(1):111-125.
21. Meng H., et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 2013, 7(2):994-1005.
22. Monopoli M.P., Bombelli F.B., Dawson K.A. Nanobiotechnology: nanoparticle coronas take shape. Nat. Nanotechnol. 2011, 6(1):11-12.
23. Monopoli M.P., et al. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 2012, 7(12):779-786.
24. Muthu M.S., et al. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics 2014, 4:660.
25. Nakamura M., et al. Identification of polyethylene glycol-resistant macrophages on stealth imaging in vitro using fluorescent organosilica nanoparticles. ACS Nano 2015, 9(2):1058-1071.
26. Nazarenus M., et al. In vitro interaction of colloidal nanoparticles with mammalian cells: what have we learned thus far?. Beilstein J. Nanotechnol. 2014, 5:1477-1490.
27. Nel A.E., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 2009, 8(7):543-557.
28. Ng K.K., Lovell J.F., Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res. 2011, 44(10):1105-1113.
29. Nohynek G.J., et al. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit. Rev. Toxicol. 2007, 37(3):251-277.
30. Pelaz B., et al. Surface functionalization of nanoparticles with polyethylene glycol: effects on protein adsorption and cellular uptake. ACS Nano 2015, 9(7):6996-7008.
31. Qian X., et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat. Biotechnol. 2008, 26(1):83-90.
32. Reese M. Nanotechnology: using co-regulation to bring regulation of modern technologies into the 21st century. Health matrix 2013, 23(2):537-572.
33. Riehemann K., et al. Nanomedicine-challenge and perspectives. Angew. Chem. Int. Ed. Engl. 2009, 48(5):872-897.
34. Rivera-Gil P., et al. The challenge to relate the physicochemical properties of colloidal nanoparticles to their cytotoxicity. Acc. Chem. Res. 2013, 46(3):743-749.
35. Salvati A., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 2013, 8(2):137-143.
36. Saptarshi S.R., Duschl A., Lopata A.L. Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. J. Nanobiotechnol. 2013, 11:26.
37. Schleh C., et al. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology 2012, 6(1):36-46.
38. Sedlacek O., et al. Poly(2-oxazoline)s - are they more advantageous for biomedical applications than other polymers?. Macromol. Rapid Commun. 2012, 33(19):1648-1662.
39. Setyawati M.I., et al. Understanding and exploiting nanoparticles' intimacy with the blood vessel and blood. Chem. Soc. Rev. 2015.
40. Shah R., et al. In vitro study of partially hydrolyzed poly(2-ethyl-2-oxazolines) as materials for biomedical applications. J. Mater. Sci. Mater. Med. 2015, 26(4).
41. Souris J.S., et al. Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials 2010, 31(21):5564-5574.
42. Tenzer S., et al. Nanoparticle size Is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 2011, 5(9):7155-7167.
43. Tenzer S., et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 2013, 8(10):772-781.
44. Torchilin V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 2014, 13(11):813-827.
45. Vogt A., et al. Interaction of dermatologically relevant nanoparticles with skin cells and skin. Beilstein J. Nanotechnol. 2014, 5:2363-2373.
46. Vroman L. Effect of absorbed proteins on the wettability of hydrophilic and hydrophobic solids. Nature 1962, 196:476-477.
47. Walczyk D., et al. What the cell "sees" in bionanoscience. J. Am. Chem. Soc. 2010, 132(16):5761-5768.
48. Walkey C.D., Chan W.C. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 2012, 41(7):2780-2799.
49. Walkey C.D., et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 2014, 8(3):2439-2455.
50. Wang F., et al. The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. Nanomedicine 2013, 9(8):1159-1168.
51. Webster T.J. Interview: nanomedicine: past, present and future. Nanomedicine 2013, 8(4):525-529.
52. Wu F., et al. Galactosylated LDL nanoparticles: a novel targeting delivery system to deliver antigen to macrophages and enhance antigen specific T cell responses. Mol. Pharm. 2009, 6(5):1506-1517.
53. Xu J., et al. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug. Chem. 2013, 24(6):915-925.
54. Yan Y., et al. Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. ACS Nano 2013, 7(12):10960-10970.
55. Yang H.W., et al. Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy. ACS Nano 2012, 6(2):1795-1805.
56. Yoo J.W., et al. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov. 2011, 10(7):521-535.
57. Zhang F., Liu M.R., Wan H.T. Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biol. Pharm. Bull. 2014, 37(3):335-339.
58. Zhang H., et al. Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size. Proteomics 2011, 11(23):4569-4577.
59. Zhao Y., et al. pH-responsive polymeric micelles based on poly(2-ethyl-2-oxazoline)-poly(d,l-lactide) for tumor-targeting and controlled delivery of doxorubicin and P-glycoprotein inhibitor. Acta Biomater. 2015, 17:182-192.